Abilify manufacturers and plaintiffs alleging the antipsychotic drug causes compulsive behavior jointly asked the U.S. Judicial Panel on Multidistrict Litigation to send federal suits to the Northern District of Florida (In re Abilify Compulsive Behavior Prod. Liab. Litig., J.P.M.L., 2734, motion filed 6/24/16).
Every plaintiff and defendant joined in the June 24 motion to transfer.
Plaintiffs sued Bristol-Myers Squibb Co., Japan-based Otsuka Pharmaceutical Co., and subsidiary Otsuka America Pharmaceutical, Inc.
They alleged the companies knew or should have known Abilify causes and exacerbates uncontrollable gambling and other behaviors, yet failed to warn patients or the medical community ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.